ClearCut Surgical Raises $3.7 Million in Seed Funding to Advance New Electrosurgery Device

First electrosurgery device to combine smoke evacuation and liquid suction targets FDA 510(k) submission and initial commercialization in 2026

BOSTON – JANUARY 21, 2026 – ClearCut Surgical, a medical device company developing a new smoke evacuation electrosurgery device, today announced the successful closure of $3.7 million in an oversubscribed Series Seed Preferred round. The company’s multifunctional, plug-and-play, single-use disposable electrosurgery device integrates with existing hospital infrastructure for seamless liquid suction and smoke evacuation. The round was led by MassVentures with additional participation from Launchpad Venture Group, Angel Investor Forum, AIF Seed Fund V, eCoast Angels, Harvard Business School Angels, and Imbolc Partners. Additional capital was contributed by family offices, private individuals, and surgeon investors. The funding will support the commercial device build, certification testing, regulatory submission, and initial commercialization efforts. 

ClearCut Surgical’s proprietary and patented four-in-one device was invented by two surgeons in Boston who experienced firsthand the limitations and ergonomic challenges of existing electrosurgery tools. The ClearCut Surgical device combines electrosurgery, liquid suction, blunt dissection, and smoke evacuation functions into a single-use disposable device, enabling surgeons to cut and cauterize tissue while simultaneously removing liquid and surgical smoke. This integrated approach reduces the need to switch between multiple devices or rely on additional assistance, helping maintain visibility and focus throughout a procedure while fitting seamlessly into existing operating room workflows.  Unlike existing smoke evacuation electrosurgery tools on the market that require additional capital expenditure to remove smoke, ClearCut Surgical’s device utilizes existing infrastructure in the operating suite.

In conjunction with the financing, ClearCut Surgical announced the appointment of Paul Hermes as chairman of the board. Mr. Hermes brings more than three decades of leadership in surgical device innovation, product development, and commercialization across global medical device organizations. He previously served as Chief Technology Officer for Covidien’s Medical Device franchise, overseeing multiple global R&D organizations, including Valleylab, during a period that fundamentally reshaped the energy and electrosurgery landscape. Over his career, Mr. Hermes has guided the development and launch of numerous benchmark surgical platforms and later founded and led Medtronic’s Hugo robotic-assisted surgery program through its formative development phase. He most recently served as chairman of BioRez, which was acquired by CONMED.

“Electrosurgery is one of the most widely used tools in surgery, yet surgeons continue to work around longstanding limitations that affect efficiency and visibility,” said Mr. Hermes.  “ClearCut Surgical brings electrosurgery, fluid suction, blunt dissection, and smoke evacuation together at the surgeon’s fingertips in a single, intuitive instrument.  Having led large surgical device portfolios and worked closely with surgeons, I recognize how meaningful that integration is in real operating rooms.  This financing supports a solution that simplifies workflow while addressing a long-standing clinical need.”

Vinit Nijhawan, Managing Director at MassVentures, also joined the board, bringing deep experience in early-stage company formation and growth.  Mr. Nijhawan has over 30 years of experience building startups, three of which were acquired by Boeing, Motorola and Qualcomm. He currently teaches entrepreneurship at Boston University in addition to his role advising and investing in startups at MassVentures.

"Led by an experienced CEO with a strong track record in medical device commercialization and grounded in surgeon-driven insight, ClearCut has a clear path toward regulatory clearance and adoption,” said Mr. Nijhawan. “At MassVentures, we're committed to supporting promising academic spinouts like ClearCut that are transforming research into commercial solutions addressing critical healthcare needs."

“Surgeons should not have to manage multiple tools and extra hands to perform routine procedures.  Our device was invented by surgeons for surgeons to address these frustrations and inefficiencies,” said Jeff Caputo, CEO of ClearCut Surgical. “We are thrilled by the support from our investors and strong interest from surgeons. This financing will allow us to complete product development, pursue 510(k) clearance, and bring this innovative solution to market.”

For more information on ClearCut Surgical, and to stay updated on future developments, please follow us on LinkedIn and visit our website www.clearcutsurgical.com 

ABOUT CLEARCUT SURGICAL

ClearCut Surgical is a Massachusetts-based medical device company developing a next-generation electrosurgery device designed to simplify surgical workflows. Co-founded by Alex Yang, MD, Heung Bae Kim, MD, and General Inception, its single-use instrument integrates electrosurgery, liquid suction, blunt dissection, and smoke evacuation into one handheld tool, helping surgeons maintain clear visualization while working more efficiently. ClearCut Surgical is advancing its lead product toward U.S. Food and Drug Administration 510(k) clearance and initial commercialization.

###

Media Contact

Andrea Vuturo

Vuturo Group for ClearCut Surgical

andrea@vuturo.com

+1 (415) 689-8414